DekaBank Deutsche Girozentrale’s ImmunityBio IBRX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-196,200	Closed	-$1.17M	–	1227
2025 Q4	$1.17M	Hold	196,200	–	–	﹤0.01%	847
2025 Q3	$497K	Hold	196,200	–	–	﹤0.01%	989
2025 Q2	$525K	Sell	196,200 -8,892	-4%	-$23.9K	﹤0.01%	976
2025 Q1	$635K	Buy	205,092 +8,892	+5%	+$26.9K	﹤0.01%	923
2024 Q4	$548K	Hold	196,200	–	–	﹤0.01%	986
2024 Q3	$782K	Hold	196,200	–	–	﹤0.01%	930
2024 Q2	$1.23M	Sell	196,200 -8,892	-4%	-$58.6K	﹤0.01%	842
2024 Q1	$1.12M	Buy	205,092 +8,892	+5%	+$40.3K	﹤0.01%	853
2023 Q4	$993K	Hold	196,200	–	–	﹤0.01%	902
2023 Q3	$309K	Hold	196,200	–	–	﹤0.01%	1122
2023 Q2	$527K	Hold	196,200	–	–	﹤0.01%	1014
2023 Q1	$336K	Hold	196,200	–	–	﹤0.01%	1100
2022 Q4	$951K	Hold	196,200	–	–	﹤0.01%	893
2022 Q3	$947K	Hold	196,200	–	–	﹤0.01%	885
2022 Q2	$724K	Hold	196,200	–	–	﹤0.01%	945
2022 Q1	$1.16M	Buy	196,200 +154,200	+367%	+$946K	﹤0.01%	886
2021 Q4	$260K	Buy	42,000 +1,000	+2%	+$7.51K	﹤0.01%	1226
2021 Q3	$389K	Hold	41,000	–	–	﹤0.01%	1103
2021 Q2	$577K	Buy	+41,000	New	+$677K	﹤0.01%	1043
2021 Q1	–	Sell	-41,000	Closed	-$540K	–	1367
2020 Q4	$540K	Buy	+41,000	New	+$394K	﹤0.01%	1007
2019 Q2	–	Sell	-32,500	Closed	-$107K	–	1217
2019 Q1	$107K	Buy	32,500 +6,000	+23%	+$7.53K	﹤0.01%	1111
2018 Q4	$29K	Sell	26,500 -6,000	-18%	-$13.7K	﹤0.01%	1155
2018 Q3	$107K	Hold	32,500	–	–	﹤0.01%	1136
2018 Q2	$97K	Hold	32,500	–	–	﹤0.01%	1109
2018 Q1	$124K	Sell	32,500 -15,900	-33%	-$69.7K	﹤0.01%	1036
2017 Q4	$273K	Hold	48,400	–	–	﹤0.01%	909
2017 Q3	$273K	Hold	48,400	–	–	﹤0.01%	915
2017 Q2	$365K	Buy	+48,400	New	+$209K	﹤0.01%	873
2016 Q3	–	Sell	-48,400	Closed	-$302K	–	989
2016 Q2	$302K	Buy	48,400 +13,500	+39%	+$105K	﹤0.01%	782
2016 Q1	$287K	Buy	+34,900	New	+$329K	﹤0.01%	773

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

DekaBank Deutsche Girozentrale's IBRX Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 196,200 shares — an estimated $1.17M sold.

DekaBank Deutsche Girozentrale first reported a position in IBRX in Q1 2016 and held it in 30 quarters. The position peaked at $1.23M in Q2 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 196,200 ImmunityBio shares in Q1 2026, an estimated $1.17M.
DekaBank Deutsche Girozentrale first reported a position in ImmunityBio in Q1 2016 and held it in 30 quarters.
DekaBank Deutsche Girozentrale's ImmunityBio position peaked at $1.23M in Q2 2024.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.